Evaluating FAP as a biomarker for fibrotic lung diseases
Official title: Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
Run by Erasme University Hospital · NCT06189820 · Data updated 2026-11-12
This study is testing if a protein called FAP can help doctors understand and track fibrotic lung diseases like idiopathic pulmonary fibrosis by looking at its levels in different samples and using special scans before and after treatments.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Erasme University Hospital Academic / other |
| Locations | 1 site (Brussels) |
| Status | Recruiting |
| Started | March 9, 2023 |
| Main results expected | March 9, 2027 |
| Study ends | March 9, 2027 |
| Registry record updated | October 16, 2026 |
| Trial ID | NCT06189820 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adult patients diagnosed with fibrotic lung diseases, specifically idiopathic pulmonary fibrosis or non-IPF ILDs.
✕Probably not a fit
Patients who are pregnant, nursing, or have significant comorbidities that may interfere with the study will not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the fibroblast activation protein (FAP) as a biomarker for fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF) and other non-IPF interstitial lung diseases (ILDs). It will involve analyzing FAP expression in various biological samples and using FAPI PET/CT scans to evaluate fibrotic activity before and after initiating different treatments, such as antifibrotic therapy, corticosteroids, and immunosuppressive drugs. The study will also correlate FAP expression with findings from lung biopsies or surgeries.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for patients with fibrotic lung diseases.
How similar studies have gone: While the use of FAP as a biomarker is a relatively novel approach, similar studies have shown promise in evaluating biomarkers for fibrotic diseases.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines Exclusion Criteria: * Pregnant or nursing patients * Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study. * Patients with an active lung neoplasm or any active neoplasm for blood samples
Where it's running
-
Medecine
Brussels, Belgium Recruiting
Study contacts
- Study coordinator: Benjamin Bondue
- Email: benjamin.bondue@hubruxelles.be
- Phone: + 32 (2) 555 5758
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Registry for individuals affected by pulmonary fibrosis
This study invites people with pulmonary fibrosis, along with their caregivers and family members, to share their experiences through online surveys to help researchers understand the condition better and possibly reach out for future studies.
-
Understanding genetic and environmental factors in pulmonary fibrosis
This study looks at how genes and environmental factors affect pulmonary fibrosis to help understand the disease better for people who have it.
-
Biobank for interstitial lung diseases
This study is setting up a collection of health information and samples from patients with interstitial lung diseases to help researchers learn more about the condition and find better treatments.
-
New IPF drug ORJ-001 tested in adults with IPF
A phase 2 study tests ORJ-001 versus placebo in adults with idiopathic pulmonary fibrosis to see if it is tolerated and whether it helps lung function.
-
Nalbuphine ER for IPF-related chronic cough
This study tests whether extended-release nalbuphine tablets can reduce chronic cough in people with idiopathic pulmonary fibrosis.
-
Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
This observational study tests how fast patients with IPF or PPF can inhale through dry powder inhalers with different resistances.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.